Aquestive Therapeutics Inc expected to post a loss of 8 cents a share - Earnings Preview

Aquestive Therapeutics

01/03/2024 21:44

* Aquestive Therapeutics Inc  AQST.OQ   AQST.O  is expected
to show a rise in quarterly revenue when it reports  results on
March 5 for the period ending December 31 2023
    * The Warren New Jersey-based  company is expected to report
a
8.9% increase in revenue to $11.631 million from $10.68 million
a year ago, according to the mean estimate from 6 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Aquestive Therapeutics
Inc is
for a loss of 8 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Aquestive
Therapeutics Inc is $6.50​, above​ its last closing price
of $3.67. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.11       -0.11      -0.03     Beat    73.5
 Jun. 30 2023  -0.12       -0.12      -0.10     Beat    15.3
 Mar. 31 2023  -0.18       -0.19      -0.12     Beat    36.5​
 Dec. 31 2022  -0.21       -0.23      -0.23     Met     0.3
 ​​Sep.        -0.31       -0.31      -0.23     Beat    26.3
 30 2022                                                
 Jun. 30 2022  -0.36       -0.36      -0.36     Met     0​
 Mar. 31 2022  -0.39       -0.41      -0.32     Beat    21.6
 Dec. 31 2021  -0.42       -0.47      -0.38     Beat    18.7
 This summary was machine generated March 1 at 21:43 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)